Last reviewed 2026-04-20 · How we verify

KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH)

MERCK SHARP DOHME · FDA-approved approved Quality 6/100

KEYTRUDA QLEX (generic name: BERAHYALURONIDASE ALFA-PMPH) is a Programmed Death Receptor-1 Blocking Antibody [EPC] drug developed by MERCK SHARP DOHME. It is currently FDA-approved.

At a glance

Generic name	BERAHYALURONIDASE ALFA-PMPH
Sponsor	MERCK SHARP DOHME
Drug class	Programmed Death Receptor-1 Blocking Antibody [EPC]
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

Nausea
Fatigue
Musculoskeletal pain

Key clinical trials

A Pilot Study of Duffy Null-Specific Dose Modifications for Individuals With Duffy Null Phenotype Receiving Standard of Care Systemic Anti-Cancer Therapies (Phase 1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KEYTRUDA QLEX CI brief — competitive landscape report
KEYTRUDA QLEX updates RSS · CI watch RSS
MERCK SHARP DOHME portfolio CI

Frequently asked questions about KEYTRUDA QLEX

What is KEYTRUDA QLEX?

KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH) is a Programmed Death Receptor-1 Blocking Antibody [EPC] drug developed by MERCK SHARP DOHME.

Who makes KEYTRUDA QLEX?

KEYTRUDA QLEX is developed and marketed by MERCK SHARP DOHME (see full MERCK SHARP DOHME pipeline at /company/merck).

What is the generic name of KEYTRUDA QLEX?

BERAHYALURONIDASE ALFA-PMPH is the generic (nonproprietary) name of KEYTRUDA QLEX.

What drug class is KEYTRUDA QLEX in?

KEYTRUDA QLEX belongs to the Programmed Death Receptor-1 Blocking Antibody [EPC] class. See all Programmed Death Receptor-1 Blocking Antibody [EPC] drugs at /class/programmed-death-receptor-1-blocking-antibody-epc.

What development phase is KEYTRUDA QLEX in?

KEYTRUDA QLEX is FDA-approved (marketed).

What are the side effects of KEYTRUDA QLEX?

Common side effects of KEYTRUDA QLEX include Nausea, Fatigue, Musculoskeletal pain.

Drug class: All Programmed Death Receptor-1 Blocking Antibody [EPC] drugs
Manufacturer: MERCK SHARP DOHME — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing